glp-1 clinical trial receptor agonists and cardiovascular outcome trials: An update 3 Takeaways from the Landmark

In Q1 2025, 29% of patients with four additional comorbidities filled a GLP-1 prescription within six months of diagnosis, compared to 19% of those with diabetes or obesity alone

Song Y, Liu X, Stielow JB, de Hoog S, Li R

Integer et est tellus non bibendum est

Thuc c rt nhiu bc s la chn v s dng cho ngi bnh

But are they safe to take alongside of the drugs used to manage RA, and do their inflammation-lowering properties translate to improvements in symptoms like joint pain and fatigue, or even slow down disease progression

Others just notice that their body does not bounce back the way it used to, and they want support without surgery or long downtime